In November, among the ten analysts covering Editas Medicine (EDIT), six analysts recommended a “buy,” while four recommended a “hold.” The mean rating for Editas Medicine stock is 2.4 with a target price of $47.29, which implies an upside potential of 75.8% over Editas Medicine’s closing price of $26.9 on November 14.
In comparison, analysts have given Bluebird Bio (BLUE), Regenxbio (RGNX), and Spark Therapeutics (ONCE) a mean rating of 1.95, 2.33, and 2.17, respectively, and target prices of $199.12, $89.08, and $63.24, respectively.
Editas Medicine stock rose from $31.40 on April 30 to $41.01 on June 20. Since then, the stock has been trending lower.
Amid the broader market turmoil in October, Editas Medicine stock saw selling pressure and fell to $24.39 on October 24. After an initial price increase in November, the company’s shares have been falling in the last few trading sessions. Currently, the shares are trading at $27 levels in November.
Editas Medicine’s enterprise value is $1.07 billion, while its enterprise value-to-revenues ratio is 36.30. The company’s price-to-sales ratio is 43.33, while the price-to-book ratio is 5.51.
Editas Medicine’s current ratio, a metric of how effectively a company can meet its short-term obligations, stands at 13.10. In comparison, CRISPR Therapeutics (CRSP), Regenxbio (RGNX), and Spark Therapeutics’ (ONCE) current ratios are 15.40, 20.20, and 10.70, respectively.